Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Cigna said its medical loss ratio was 87.9% in Q4 2024, compared to 82.2% in the prior-year quarter. For the full-year 2024, MLR was 83.2%, which was still higher compared to the 81.3% its insurance ...

Shares of Elevance Health Inc. ELV shed 1.26% to $400.30 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 ...

After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other ...

Q4 2024 Earnings Call Transcript January 23, 2025 Elevance Health Inc. beats earnings expectations. Reported EPS is $3.84, expectations were $3.8. Operator: Ladies and gentlemen, thank you for ...

Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...

Mizuho Securities analyst Ann Hynes has maintained their bullish stance on ELV stock, giving a Buy rating on January 16.Invest with ...

Elevance Health, Inc. ELV reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.84, which surpassed the Zacks Consensus Estimate by 1.1%. However, the bottom line deteriorated 31.7% ...

Elevance Health (NYSE: ELV) Q4 2024 Earnings Call Jan 23, 2025, 8:30 a.m. ET ...